According to Palatin Technologies's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.540541. At the end of 2022 the company had a P/E ratio of -0.8179.
Year | P/E ratio | Change |
---|---|---|
2022 | -0.8179 | -76.52% |
2021 | -3.48 | -43.65% |
2020 | -6.18 | -242.66% |
2019 | 4.33 | -102.28% |
2018 | -190 | -2967.4% |
2017 | 6.62 | -489.14% |
2016 | -1.70 | -15% |
2015 | -2.00 | -97.26% |
2014 | -73.0 | 1400% |
2013 | -4.87 | 297.44% |
2012 | -1.22 | 36.17% |
2011 | -0.8992 | -29.39% |
2010 | -1.27 | -112.39% |
2009 | 10.3 | -2041.36% |
2008 | -0.5294 | -49.71% |
2007 | -1.05 | -76.78% |
2006 | -4.53 | -42.99% |
2005 | -7.95 | 16.58% |
2004 | -6.82 | 63.69% |
2003 | -4.17 | 104.12% |
2002 | -2.04 | -44.11% |
2001 | -3.65 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 11.2 | -2,174.68% | ๐บ๐ธ USA |
AstraZeneca AZN | 34.4 | -6,461.76% | ๐ฌ๐ง UK |
Neurocrine Biosciences
NBIX | 70.3 | -13,109.45% | ๐บ๐ธ USA |
MediciNova MNOV | -5.88 | 987.80% | ๐บ๐ธ USA |
Ligand Pharmaceuticals LGND | 45.4 | -8,498.05% | ๐บ๐ธ USA |
Dicerna Pharmaceuticals DRNA | N/A | N/A | ๐บ๐ธ USA |
ANI Pharmaceuticals ANIP | -148 | 27,331.22% | ๐บ๐ธ USA |
GlycoMimetics
GLYC | -4.89 | 805.08% | ๐บ๐ธ USA |
Ardelyx ARDX | -61.8 | 11,323.74% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.